Akkermansia Muciniphila Side Effects: What Clinical Trials and Users Report

Akkermansia muciniphila has moved from microbiome research papers to supplement store shelves with unusual speed, and the questions most people ask are practical: what does it actually feel like to take, what do clinical trials report on safety, and who should be cautious? This article gathers what the published research and user accounts say about side effects, tolerability, and risk considerations, without overstating the current evidence base.

Akkermansia supplements are not FDA-approved to treat or cure any condition, and the human trial data, while broadly reassuring, is still early and limited in long-term follow-up. If you are immunocompromised, taking immunosuppressive therapy, managing active inflammatory bowel disease, or undergoing cancer treatment, you should speak with a physician before adding any live probiotic to your routine. What follows is informational, not medical advice.

How Akkermansia Works, and Why That Matters for Safety

Akkermansia muciniphila is a gram-negative bacterium that colonises the gut’s mucus layer, comprising more than 1% of the microbiome in healthy adults. Its proposed mechanisms include mucin degradation that drives mucus layer renewal, upregulation of tight-junction proteins that reinforce intestinal barrier integrity, and signalling through its outer-membrane protein Amuc_1100, which interacts with toll-like receptor 2 and is proposed to stimulate GLP-1 secretion. These pathways come mostly from cell and mouse work; one small human pilot reported better insulin sensitivity with pasteurized Akkermansia, but a larger trial missed its primary endpoint ^[9][6].

Understanding the mechanism matters for safety because Akkermansia is not a conventional lactic-acid probiotic. Being gram-negative, it carries lipopolysaccharide (LPS) on its cell membrane. In individuals with a significantly compromised gut barrier, LPS can trigger inflammatory responses. This is one reason researchers have explored pasteurised rather than live formulations, and it anchors the theoretical risk profile for people with severe intestinal permeability issues or active systemic immune activation.

What Clinical Trials Report on Tolerability

Human intervention trials that have enriched or directly administered Akkermansia have generally reported a mild adverse-event profile. Trials that gave Akkermansia directly are few. In a 2019 placebo-controlled pilot of live and pasteurised A. muciniphila in 40 overweight or obese insulin-resistant adults, EFSA noted no difference between groups in nausea, flatulence, bloating, cramps or reflux, but judged the pilot of limited value for safety. In a 142-adult metabolic syndrome trial, adverse events were balanced between pasteurized MucT and placebo ^[8][6].

A trial of pasteurized A. muciniphila HB05P in 100 adults aged 60 and over recorded mild or moderate adverse events in 4 participants (1 on HB05P, 3 on placebo), none judged related to the product; three of its authors were employed by the maker. Company statements given to EFSA about post-marketing safety are company-reported, not independent ^[10][11].

The broader probiotic, prebiotic, and synbiotic literature, including studies examined in the context of obesity and metabolic outcomes, confirms that GI-related symptoms are the most common adverse-event category, while serious adverse events remain rare in otherwise healthy or metabolically compromised adults ^[1]. In mice, both live and pasteurized A. muciniphila showed no adverse effects in colon, liver or adipose tissue histology, and in rats given pasteurized A. muciniphila for 90 days no test-item-related adverse effects were seen at the highest dose tested, though animal findings cannot be directly extrapolated to humans ^[12][7].

Common Self-Reported Side Effects

User-reported experiences, drawn from online communities and product reviews, most commonly describe transient gastrointestinal symptoms in the first one to two weeks of supplementation. These include mild bloating, increased gas, and loose stools: experiences familiar with any probiotic or prebiotic intervention that shifts gut microbiome composition. The majority of users who report these symptoms note that they resolve as the gut adjusts.

Less commonly, users report mild nausea, particularly when capsules are taken on an empty stomach. A meaningful subset reports no GI effects at all. Reports of persistent or severe symptoms are uncommon, and any GI disturbance that does not resolve within two to three weeks, or that is severe, should prompt discontinuation and a conversation with a clinician. There is no large-scale, systematically collected user-safety database specifically for Akkermansia products, so user reports are inherently anecdotal and subject to reporting bias in both directions.

Who Should Exercise Caution

Immunocompromised individuals represent the population for whom caution is most clearly warranted. This includes people receiving chemotherapy, organ transplant recipients on immunosuppressive regimens, and individuals with HIV or primary immune deficiencies. Live probiotic organisms carry a theoretical risk of bacteraemia or systemic infection when gut integrity is compromised and immune surveillance is reduced. The general probiotic safety literature documents rare but real cases of sepsis in immunocompromised hosts ^[1]. No Akkermansia-specific case report is in the evidence reviewed, so this is a caution drawn from probiotics in general ^[1][16].

People with active inflammatory bowel disease (IBD) occupy a nuanced position. Although some studies report lower Akkermansia in IBD, others find no overall difference, and restoring it is an active research target ^[13][14][15], the acutely inflamed gut during a flare may respond differently to probiotic supplementation than a healthy intestine. The microbiome’s interaction with immunotherapy in extra-intestinal cancers, where Akkermansia has been implicated in modulating treatment response ^[3]means that cancer patients on checkpoint inhibitors should treat Akkermansia supplementation as a decision requiring their oncology team’s input.

Mouse studies add a caution. In mice lacking the Il10 gene, A. muciniphila alone was enough to promote intestinal inflammation, and the authors concluded it can act as a pathobiont in a genetically susceptible host. A critical review also says supplementation may not benefit inflammatory bowel disease ^[22][23].

EFSA concluded in 2025 that the safety of pasteurised A. muciniphila in pregnant and lactating women has not been established; the only pregnancy data it reviewed came from a mouse study ^[11]. As with all supplement categories where evidence in this population is absent, consultation with an obstetrician or midwife before use is the appropriate standard.

Pasteurised vs. Live Formulations: Does It Change the Risk?

Akkermansia supplements are sold in both pasteurised and live forms; EFSA authorised only the pasteurised form, and live refrigerated products such as Pendulum’s are also on the market ^[11][18]. The stated rationale for inactive forms is practical, since A. muciniphila is sensitive to oxygen and difficult to stabilise in an oral dose form. In mice, the Amuc_1100 protein withstands pasteurisation temperatures, but whether live or pasteurised cells work better is unresolved ^{[19][20][21][12]}.

From a safety standpoint, pasteurised formulations theoretically carry a lower risk of bacteraemia because the organisms cannot replicate or translocate. However, gram-negative bacterial cell walls retain LPS even after pasteurisation, meaning that pattern-recognition receptor stimulation remains possible in individuals with severely compromised intestinal barriers. The degree to which this is clinically meaningful at typical supplement doses has not been rigorously established. In practice, both live and pasteurised formats should still be treated as requiring physician approval for immunocompromised individuals and others in high-risk categories.

Drug Interactions and Special Clinical Situations

No well-characterised pharmacokinetic drug-drug interactions for Akkermansia supplements have been established in controlled clinical studies. However, several interaction categories warrant attention. Immunosuppressants, including calcineurin inhibitors used in transplantation and biologics used for autoimmune conditions, reduce the immune surveillance that ordinarily limits probiotic organisms in the gut and systemic circulation; concurrent use of any live probiotic alongside these agents requires medical guidance ^[1].

Antibiotics are a practical consideration: broad-spectrum antibiotic courses can significantly deplete Akkermansia and other gut commensals. In mice with colitis-associated colorectal cancer, giving A. muciniphila after antibiotics worsened tumour burden, and the authors concluded that probiotics should be used with caution after antibiotic treatment. This is mouse work, but it underscores that the timing and context of any microbiome-modifying intervention matter ^[17]. If a course of antibiotics is planned, discussing Akkermansia timing with a clinician or pharmacist is reasonable.

In oncology, evidence that Akkermansia abundance correlates with improved response to checkpoint-inhibitor immunotherapy ^[3] has generated genuine research interest. But this also means that cancer patients on immunotherapy should not self-administer Akkermansia supplements, as microbiome composition during active treatment is a consequential variable that oncologists may be actively managing.

What the research says

Human clinical data on Akkermansia muciniphila as a supplement is promising but limited. The most cited human study is Depommier and colleagues’ 2019 pilot trial in Nature Medicine, which randomised 40 overweight or obese insulin-resistant adults (32 completed) to placebo, live, or pasteurized A. muciniphila at 10¹⁰ cells daily. Both bacterial arms were reported safe and well tolerated across three months, with no difference between groups in nausea, flatulence, bloating or cramps^[4]. EFSA judged the pilot of limited value for safety because it had few subjects, a low dose and a short duration ^[4][8]. (A frequently repeated version of this attributes the trial to Plovier and colleagues; that 2017 paper is a study in mice, not people.)

Two substantially larger trials have since reported. A 2026 trial followed 90 adults through an 8-week low-energy diet and a 24-week maintenance phase on daily pasteurized A. muciniphila, observing no treatment-related serious adverse events^[5]. A 2026 multicentre trial in 142 adults with metabolic syndrome ran four months and, while it missed its primary efficacy endpoint, raised no safety signal^[6].

One caveat that applies to all of them: the human safety record for this supplement rests almost entirely on trials run, staffed, or co-founded by the company that sells it. The 2019 authors disclose that they are patent holders and co-founders of the commercial developer, and both 2026 trials list employees, consultants or co-founders of The Akkermansia Company among their authors^[4][5][6]. That does not make the results wrong, and all three are registered trials in peer-reviewed journals. It does mean there is no large, fully independent safety dataset to check them against yet.

However, “no serious adverse events in a small, short trial” is not the same as a comprehensive safety record. Here is what the current evidence actually covers:

Common reported side effects in trials: In the 2019 pilot, EFSA noted no difference between groups in nausea, flatulence, bloating, cramps or reflux. Loose stools, gas and bloating are reported anecdotally by some users ^[8].

Dosing safety: Most human research has used pasteurized (heat-killed) A. muciniphila, not live bacteria. Pasteurized forms are considered lower risk because the bacteria cannot replicate in the gut. Live-culture products exist commercially but have less human safety data behind them. EFSA’s 2021 opinion found pasteurised A. muciniphila safe for adults, excluding pregnant and lactating women, at 3.4 × 10^10 cells per day; no higher human limit has been established ^[8]. The nearest thing is a regulatory toxicology package in which rats given pasteurized A. muciniphila daily for 90 days showed no adverse effects at the highest dose tested, setting a no-observed-adverse-effect level of 9.6 × 10¹⁰ cells per kg of body weight per day, alongside negative genotoxicity assays^[7]. That is an animal safety margin supporting use as a food ingredient, not a human dosing ceiling, and it should not be read as one.

Pregnancy and breastfeeding: EFSA concluded in 2025 that safety in pregnant and lactating women has not been established; the only pregnancy data it reviewed came from a mouse study ^[11]. Standard precautionary guidance applies: avoid unless a clinician specifically advises otherwise.

Immunocompromised individuals: People on immunosuppressive therapy, those who have undergone organ transplants, or anyone with a significantly compromised immune system should consult a physician before using any probiotic, including A. muciniphila. In theory, introducing live bacteria into a suppressed immune environment carries risks that do not apply to healthy adults, and a review of probiotics in general reports infections, sepsis and bacteraemia in immunocompromised patients ^[16].

Drug interactions: No well-documented drug interactions have been established. That said, A. muciniphila influences gut barrier function, bile acid metabolism, and inflammation pathways, all of which can theoretically interact with medications that depend on gut absorption or microbiome activity. If you take immunosuppressants, anticoagulants, or medications with a narrow therapeutic window, speak to your pharmacist or prescriber first.

Quality and contamination concerns: The supplement market is not uniformly regulated. Because A. muciniphila is an anaerobic organism, it is sensitive to oxygen during manufacturing. Products that are poorly handled may contain far fewer viable organisms than advertised, or in the case of live products, potentially inconsistent bacterial loads. Choosing brands with third-party testing and transparent manufacturing practices matters more here than with many other supplements.

---

A Note on the Evidence

The human trial evidence for Akkermansia muciniphila safety is encouraging but limited in scale and duration; the available data come from a few small, short direct-supplementation trials, some involving authors employed by or co-founding the product’s makers, and there are no long-term data ^[6][10][8]. Akkermansia supplements are not FDA-approved to treat, cure, or prevent any disease, and live probiotic formulations carry real risk for immunocompromised individuals, those on immunosuppressive therapy, and persons with active inflammatory bowel disease or cancer undergoing immunotherapy: these individuals should consult a qualified physician before use.

Frequently Asked Questions

Is Akkermansia safe to take daily?

In the small trials that gave Akkermansia directly, adverse events were balanced with placebo over the short study periods ^[8][6]. However, long-term safety data beyond a few months are limited, and Akkermansia supplements are not FDA-approved. Daily use by immunocompromised individuals, those on immunosuppressive drugs, or people with active IBD is not recommended without physician guidance.

Can Akkermansia cause digestive upset?

Transient digestive symptoms (bloating, gas, and loose stools) are the most commonly self-reported effects, consistent with what the broader probiotic and gut-microbiome-modulating literature describes ^[1]. These typically appear in the first one to two weeks and resolve without intervention. Persistent or severe GI symptoms should prompt discontinuation and evaluation by a clinician.

Is Akkermansia safe for people with cancer?

This requires case-by-case medical guidance. Research indicates that Akkermansia abundance may influence responses to checkpoint-inhibitor immunotherapy in extra-intestinal cancers ^[3], and Akkermansia modulation has been tracked as an outcome in cancer patient trials ^[2]. This means supplementing with Akkermansia during cancer treatment is not a straightforward self-care decision: patients should discuss it with their oncology team.

Can Akkermansia supplements be taken alongside antibiotics?

Antibiotics can significantly reduce gut bacterial populations including Akkermansia. In mice with colitis-associated colorectal cancer, giving A. muciniphila after antibiotics worsened tumour burden. While taking probiotics ^[17] after antibiotics is common practice, there is no specific clinical guidance on optimal timing for Akkermansia; discussing timing with a clinician or pharmacist is reasonable, especially for long or broad-spectrum courses.

Are pasteurised Akkermansia supplements safer than live ones?

Pasteurised formulations cannot replicate or translocate, making bacteraemia theoretically less likely. In mice the Amuc_1100 protein withstands pasteurisation temperatures, but whether that explains any effect of pasteurised cells in people is unproven ^[20]. That said, LPS from gram-negative cell walls remains present in killed cells, and neither format is categorically safe for immunocompromised individuals. Trials of pasteurised formulations in adults have reported adverse events balanced with placebo, but EFSA judged the 2019 pilot of limited value for safety and long-term data are limited ^[6][8].

Who should not take Akkermansia supplements?

Individuals who should avoid Akkermansia without physician approval include: immunocompromised persons (those undergoing chemotherapy, organ transplant recipients, individuals with HIV); people taking immunosuppressive medications or biologics; those with active IBD flares; cancer patients on immunotherapy; pregnant or breastfeeding individuals; and children; no paediatric trial data are in the evidence reviewed, although EFSA’s 2025 opinion set daily limits for pasteurised product in adolescents aged 12 to under 18 ^[11]. This list is not exhaustive, when uncertain, consult a qualified healthcare provider.

References

1. Vallianou N et al. Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives. Current obesity reports (2020). PMID 32472285
2. Mandl A et al. Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant. The Prostate (2025). PMID 40325900
3. Mattavelli E et al. Harnessing the gut microbiota in extra-intestinal cancers: from causal evidence to immunotherapy strategies. Immunotherapy (2026). PMID 41873461
4. Depommier C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine (2019). PMID 31263284
5. Mount S, Canfora EE et al. Pasteurized Akkermansia muciniphila Muc(T) for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nature Medicine (2026). PMID 42120725
6. Suenaert P et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome. Gut Microbes (2026). PMID 42343233
7. Druart C et al. Toxicological safety evaluation of pasteurized Akkermansia muciniphila. Journal of Applied Toxicology (2021). PMID 32725676
8. European Food Safety Authority (NDA Panel) Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. European Food Safety Authority (NDA Panel) (2021). source
9. Liu Y et al. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities. Frontiers in pharmacology (2026). PMID 42846334
10. Kang CH et al. Pasteurized Akkermansia muciniphila HB05 (HB05P) Improves Muscle Strength and Function: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients (2024). PMID 39683431
11. EFSA Panel on Nutrition et al. Safety of an extension of use of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. EFSA journal. European Food Safety Authority (2025). PMID 41018002
12. Fatemeh Ashrafian et al. Comparative effects of alive and pasteurized Akkermansia muciniphila on normal diet-fed mice. Scientific Reports (2021). PMID 34504116
13. Cao X et al. Detection of tissue colonizing bacteria and their association with clinicopathological and molecular features of inflammatory bowel disease. Journal of translational medicine (2025). PMID 41094525
14. Mireia López‐Siles et al. Alterations in the Abundance and Co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Colonic Mucosa of Inflammatory Bowel Disease Subjects. Frontiers in Cellular and Infection Microbiology (2018). PMID 30245977
15. Mengyu Zheng et al. The role of Akkermansia muciniphila in inflammatory bowel disease: Current knowledge and perspectives. Frontiers in Immunology (2023). PMID 36685588
16. Fijan S Microorganisms with claimed probiotic properties: an overview of recent literature. International journal of environmental research and public health (2014). PMID 24859749
17. Wang K et al. The negative effect of Akkermansia muciniphila-mediated post-antibiotic reconstitution of the gut microbiota on the development of colitis-associated colorectal cancer in mice. Frontiers in microbiology (2022). PMID 36312913
18. Pendulum Therapeutics Pendulum Akkermansia (product page). Pendulum Therapeutics source
19. Fatemeh Ashrafian et al. Extracellular vesicles and pasteurized cells derived from Akkermansia muciniphila protect against high-fat induced obesity in mice. Microbial Cell Factories (2021). PMID 34863163
20. Plovier H et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature medicine (2017). PMID 27892954
21. Amandine Everard et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences (2013). PMID 23671105
22. Sergey S. Seregin et al. NLRP6 Protects Il10 Mice from Colitis by Limiting Colonization of Akkermansia muciniphila. Cell Reports (2017). PMID 28445725
23. Chiantera V et al. A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms. Life (Basel, Switzerland) (2023). PMID 37374030

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.